Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 357

Ovid to go over to public markets

Sanofi and Takeda-backed Ovid Therapeutics has filed to raise $86.3m in an initial public offering and plans to use the proceeds to advance its neurological disease treatments.

Apr 13, 2017

ReNew Power targets $600m in IPO charge

The wind and solar power producer has raised more than $850m in total equity funding, including $200m from Tokyo Electric Power and Chubu Electric Power this year.

Apr 10, 2017

Big Deal: Sina exits Toutiao in $1bn round

The social media company has scored a huge exit from news app Toutiao, exiting as part of a series D round that valued it at $11bn, 22 times the valuation at which Sina invested in 2014.

Apr 10, 2017

Allied Minds cuts off funds to seven spinouts

Tinnitus Treatment Solutions and food standards and sanitation company RF Biocidics are among the casualties of the $146.6m writedown, with capital being diverted to more promising subsidiaries.

Apr 7, 2017

Square enters talks for Yik Yak acquisition

The Renren-backed social media platform, once valued at up to $400m, is in talks with Square for an acqui-hire deal.

Apr 7, 2017

Spotify scutinises public listing options

The corporate-backed music platform is reportedly mulling a public market listing that would not raise money but which would allow investors to divest their shares.

Apr 7, 2017

PetCoach gets a new owner

Petco has purchased petcare services platform PetCoach for an undisclosed sum, providing an exit to corporate investors Comcast and Pet360.

Apr 5, 2017

Grab pays up to $100m for Kudo

Grab has completed the acquisition of Emtek, Gree and Singapore Press Holdings-backed mobile payment portal Kudo for between $80m and $100m.

Apr 5, 2017

Cohesity stores away $90m

GV has led a series C round that valued the secondary storage technology provider at more than $500m with backing from Cisco, Qualcomm and Hewlett Packard Enterprise.

Apr 5, 2017

Zymeworks looks to construct $75m IPO

Eli Lilly is the oncology antibody developer's largest shareholder, while other investors include Celgene and EMS subsidiary Brace Pharma Capital.

Apr 5, 2017
© 2026 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here